Gemelli Biotech, a Los Angeles, CA and Raleigh, NC-based firm targeted on bettering well being by offering precision diagnostics for gastrointestinal (GI) illnesses, raised $19M in Sequence A funding.
The spherical was led by Blue Ox Healthcare Companions, Cedars-Sinai, with participation from Cedars-Sinai, Carolina Angel Community, CerraCap Ventures, and a number of other household places of work.
Based in 2018 and led by CEO Matt Mitcho, Gemelli Biotech is targeted on bettering well being by offering precision diagnostics for GI illnesses. The corporate leverages organic discoveries associated to the microbiome to offer non-invasive precision diagnostics which allow clinicians to definitively detect scientifically validated biomarkers and optimally deal with GI illnesses together with SIBO, IMO, extra hydrogen sulfide, and post-infectious IBS.
Gemelli Biotech intends to make use of the funds to speed up the commercialization of its trio-smart® and ibs-smart® precision diagnostic assessments, together with increasing gross sales and advertising and marketing throughout the US and the scale-up of laboratory and manufacturing capability, in addition to its operational footprints in Raleigh and Los Angeles.
trio-smart is a medical breath take a look at that measures ranges of hydrogen, methane, and hydrogen sulfide to offer clinicians and sufferers with a extra full image of intestine well being. ibs-smart is a patented diagnostic blood take a look at for post-infectious irritable bowel syndrome (IBS). Each merchandise have been developed in partnership with the Medically Related Science and Expertise program at Cedars-Sinai.